Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072917 | 0.99 | EGFR (0.35) | TDP1EGFRHDAC3SMN1; SMN2 | |
| SCHEMBL7070270 | 0.96 | TDP1 (0.35) | TDP1EGFRHDAC3KDM4ECYP2C19 | |
| SCHEMBL7074143 | 0.94 | TDP1 (0.36) | TDP1EGFRHDAC3KDM4ENPC1 | |
| SCHEMBL7072779 | 0.93 | EGFR (0.37) | TDP1EGFRHDAC3KDM4ENPC1 | |
| SCHEMBL7072969 | 0.92 | MAOB (0.32) | — | |
| SCHEMBL7069086 | 0.90 | TDP1 (0.37) | TDP1EGFRHDAC3KDM4ENPC1 | |
| SCHEMBL7068786 | 0.87 | MAOB (0.33) | TDP1KDM4ENPC1LMNARAB9A | |
| SCHEMBL7072574 | 0.86 | — | — | |
| SCHEMBL7072813 | 0.85 | MAOB (0.38) | TDP1KDM4ECYP3A4NPC1LMNA | |
| Butadiene SCHEMBL7075360 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | NABIKA MASAAKI (JP) | 2003-06-12 | — | — | US | disclosed |
| US-6528671-B1 | Such as cyclopentadienyl-trimethylphosphineimine-1,4-di-phenyl butandiene titanium complex; copolymerization of ethylene with other alpha-olefins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | ARL1, AP2M1, AP1M1 | TDP1 4039/4885EGFR 1661/4885HDAC3 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.